Daniel E Abbott
Overview
Explore the profile of Daniel E Abbott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
213
Citations
3119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marcinak C, Abbott D
Cancer Treat Res
. 2024 Aug;
192:147-163.
PMID: 39212920
Gallbladder carcinoma (GBC) is the most common biliary epithelial malignancy, with an estimated incidence of 1.13 cases per 100,000 in the United States (Hundal and Shaffer in Clin Epidemiol 6:99-109,...
2.
Marcinak C, Ahmed K, Loconte N, Praska C, Varley P, Weber S, et al.
J Surg Oncol
. 2024 Jul;
130(3):462-475.
PMID: 39082628
Background And Objectives: Pancreaticoduodenectomy (PD), the only surgical option for right-sided pancreatic ductal adenocarcinoma (PDAC), carries significant morbidity. Not all patients may be deriving a survival benefit from this operation....
3.
4.
Fackche N, Schmocker R, Nudotor R, Kubi B, Cloyd J, Grotz T, et al.
Ann Surg Oncol
. 2024 Feb;
31(5):3314-3324.
PMID: 38310181
Introduction: Patients with colorectal peritoneal metastases (CRPM) are increasingly treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Unfortunately, data identifying preoperative risk factors for poor oncologic outcomes after this...
5.
Ogobuiro I, Baca Y, Ribeiro J, Walker P, Wilson G, Gulhati P, et al.
JCO Precis Oncol
. 2023 Nov;
7:e2300152.
PMID: 37944072
Purpose: Using a real-world database with matched genomic-transcriptomic molecular data, we sought to characterize the distinct molecular correlates underlying clinical differences between patients with young-onset pancreatic cancer (YOPC; younger than...
6.
Florissi I, Radomski S, Shou B, Cloyd J, Kim A, Grotz T, et al.
J Surg Res
. 2023 Oct;
293:403-412.
PMID: 37806228
Introduction: We explored the association between weekend discharge and 30- and 90-d readmission rates in patients undergoing hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for peritoneal carcinomatosis. Methods: The US HIPEC Collaborative database,...
7.
Marcinak C, Praska C, Vidri R, Taylor A, Krebsbach J, Ahmed K, et al.
Ann Surg Oncol
. 2023 Oct;
31(1):488-498.
PMID: 37782415
Background: While lower socioeconomic status has been shown to correlate with worse outcomes in cancer care, data correlating neighborhood-level metrics with outcomes are scarce. We aim to explore the association...
8.
Logan C, Hudnall M, Schlick C, French D, Bartle B, Vitello D, et al.
JAMA Netw Open
. 2023 Sep;
6(9):e2335311.
PMID: 37768664
Importance: Venous thromboembolism (VTE) represents a major source of preventable morbidity and mortality and is a leading cause of death in the US after cancer surgery. Previous research demonstrated variability...
9.
SenthilKumar G, Merrill J, Maduekwe U, Cloyd J, Fournier K, Abbott D, et al.
J Surg Res
. 2023 Sep;
292:275-288.
PMID: 37666090
Introduction: In patients with disseminated appendiceal cancer (dAC) who underwent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), characterizing and predicting those who will develop early recurrence could provide a...
10.
Benson A, DAngelica M, Abrams T, Abbott D, Ahmed A, Anaya D, et al.
J Natl Compr Canc Netw
. 2023 Jul;
21(7):694-704.
PMID: 37433432
In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for...